Dipartimento di Medicina Molecolare

Contenuti del sito

Menu di navigazione - Torna all'inizio


Contenuto della pagina - Torna all'inizio


Palladini Giovanni

Professore Associato
Sede:
Biochimica Clinica
Centro per lo Studio e la Cura delle Amiloidosi Sistemiche
Padiglione Forlanini (ultimo piano)
Fondazione IRCCS Policlinico San Matteo
Viale Golgi, 19 - 27100 Pavia

Telefono(+39)0382.502994
Fax0382-502990
E-mailgiovanni.palladini@unipv.it
Orari di ricevimentoPreferisco essere contattato via e-mail
Insegnamenti
Insegnamenti:
1. Medicina di Laboratorio (Medicina e Chirurgia, LM)
2. Metodologia Diagnostica Molecolare (Biotecnologie, L)
3. Biochimica Clinica e Biologia Molecolare Clinica (Scienze delle Professioni Sanitarie Tecniche e Assistenziali, LM)
4. Biochimica Clinica e Biologia Molecolare Clinica (Scienze delle Professioni Sanitarie Tecniche e Diagnostiche, LM)

CurriculumCV Palladini
Pubblicazioni1. Wechalekar AD, Schoenland S, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G. A European collaborative study of treatment outcomes in 346 Patients with Stage III AL amyloidosis. Blood 2013 (in press).
2. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar AD, Hawkins PN, Schönland S, Hegenbart U, Comenzo R, Kastritis S, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in AL amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30: 4541-4549.
3. Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, Palladini G. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010; 28: 1031-1037.
4. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, Cavallero G, Rustichelli R, Virga G, Merlini G. The association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis ineligible for stem cell transplantation. Blood 2004; 103: 2936-2938.
5. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, Melzi D’Eril G, Moratti R, Merlini G. Serum N-terminal pro Brain Natriuretic Peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440-2445.

Collaborazioni1. Department of Medicine, Department of Laboratory Medicine, Department of Hematology Mayo Clinic, Rochester, MN, USA.
2. National Amyloidosis Centre, University College London Medical School, London, United Kingdom.
3. Amyloidosis Center, Department of Internal Medicine, Division of Hematology / Oncology / Rheumatology, University of Heidelberg, Heidelberg.
4. Tufts Medical Center, Boston, MA, USA.
5. Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece.
6. Département de Clinique Hematologie, Université de Limoges, Centre de Référence des Amyloses Primitives et des Autres Maladies de Dépôts d’Immunoglobuline Monoclonale, CHU de Limoges, Limoges, France.
7. Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy
8. University of Groningen, Groningen, The Netherlands
9. Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic, University of Barcelona, Barcelona, Spain